申请人:Sarubbi Donald J.
公开号:US20100016229A1
公开(公告)日:2010-01-21
The present invention provides pharmaceutical compositions comprising of at least one delivery agent and GLP-1. These pharmaceutical compositions facilitate the oral delivery of GLP-1, providing improved (e.g. increased) bioavailability of GLP-1 compared to administration of GLP-1 without a delivery agent.
本发明提供了包含至少一种传递剂和GLP-1的药物组合物。这些药物组合物促进了GLP-1的口服给药,相比于没有传递剂的GLP-1给药,提高了GLP-1的生物利用度(例如,增加了生物利用度)。